Veterinary Immunodiagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay, Rapid Tests, Other), By Application (Cattle, Pigs, Poultry, Feline, Canine, Equine, Other), Regional Insights and Forecast From 2026 To 2035

Veterinary Immunodiagnostics Market Overview

The global veterinary immunodiagnostics market is estimated to reach USD 1,015.95 million in 2026 and grow to USD 2,271.41 million by 2035. This expansion reflects a compound annual growth rate (CAGR) of 9.35% during the forecast period from 2026 to 2035. The projected increase of USD 1,255.46 million over nine years indicates sustained market growth, with the anticipated valuation in 2035 reaching more than double the estimated size in 2026.

The Veterinary Immunodiagnostics Market supports animal disease detection through antigen-antibody technologies used across companion animals, livestock, poultry, and equine healthcare. Enzyme-Linked Immunosorbent Assay (ELISA) remains the leading technology with approximately 36.75% market share because of established laboratory workflows, high specificity, scalability, and broad infectious-disease applications. Immunodiagnostic platforms increasingly combine rapid assays, lateral-flow formats, automated readers, digital connectivity, and multiplex testing. Veterinary clinics, reference laboratories, farms, and animal-health programs use these technologies for infectious disease screening, herd-health monitoring, preventive testing, and zoonotic disease surveillance, strengthening demand for reliable, fast, and increasingly decentralized diagnostic solutions.

The USA Veterinary Immunodiagnostics Market is supported by advanced veterinary clinics, reference laboratories, companion-animal healthcare, livestock disease surveillance, and extensive point-of-care diagnostic adoption. Veterinary practices increasingly use immunodiagnostic assays for canine vector-borne diseases, feline infectious diseases, heartworm, gastrointestinal infections, reproductive conditions, and livestock health monitoring. Large diagnostic companies continue expanding connected analyzers, automated rapid-test interpretation, reference laboratory services, and artificial intelligence-assisted clinical workflows. Preventive veterinary care, pet insurance participation, livestock biosecurity, and faster treatment decisions are encouraging greater test utilization. Competition increasingly centers on assay accuracy, turnaround time, instrument connectivity, multiplex testing, laboratory integration, and recurring diagnostic consumables.

Key Findings

• Market Size and Forecast: Veterinary Immunodiagnostics Market reaches USD 1,015.95 million in 2026 and USD 2,271.41 million by 2035 at 9.35% CAGR.
• Type Leadership: ELISA leads with approximately 36.75% share, supported by high specificity, laboratory adoption, infectious-disease surveillance, scalable testing, and established veterinary workflows.
• Application Leadership: Canine applications hold approximately 33% report share, supported by preventive screening, vector-borne disease testing, companion-animal healthcare, and rapid diagnostics adoption.
• Key Company Landscape: Idexx Laboratories and Zoetisinc strengthen competition through rapid assays, connected analyzers, reference laboratories, artificial intelligence, and veterinary diagnostic innovation.
• Fastest Growing Region: Asia-Pacific expands fastest through pet adoption and livestock biosecurity, while North America retains approximately 41.2% leading market share.
• Key Trends: Point-of-care immunodiagnostics increasingly deliver results within minutes, while multiplex platforms can screen a single veterinary sample for 7 pathogens.

Latest Trends

The Veterinary Immunodiagnostics Market is shifting toward rapid point-of-care testing, connected diagnostic platforms, multiplex assays, artificial intelligence-assisted interpretation, and integrated reference laboratory workflows. ELISA continues to represent approximately 36.75% of market activity because veterinary laboratories rely on established antibody and antigen detection protocols for surveillance and routine screening. At the same time, rapid tests are increasingly important where veterinarians require same-visit clinical decisions. Modern canine immunodiagnostic platforms can screen a single sample for 7 vector-borne pathogens, increasing diagnostic breadth without requiring separate manual tests.

Automation is another major Veterinary Immunodiagnostics Market trend. Reader-supported lateral-flow platforms reduce subjective visual interpretation and automatically capture test results into veterinary information systems. Veterinary diagnostics companies are expanding cloud connectivity, specialist consultation, automated image analysis, and artificial intelligence-supported workflows. Livestock producers increasingly use immunodiagnostics for herd surveillance, biosecurity, reproductive management, and infectious disease monitoring. Companion-animal clinics are adopting multiplex testing for heartworm, tick-borne diseases, feline leukemia, feline immunodeficiency virus, Giardia, and parvovirus. Manufacturers are also improving reagent stability, room-temperature storage, sample flexibility, test sensitivity, and workflow standardization. These advances support greater diagnostic decentralization while maintaining connections between veterinary clinics and specialist laboratories.

Market Dynamics

DRIVER

"Rising demand for rapid infectious disease detection and preventive animal healthcare."

The primary driver of the Veterinary Immunodiagnostics Market is increasing demand for earlier diagnosis of infectious and immune-related animal diseases. Immunodiagnostic assays allow veterinarians to detect pathogen antigens, host antibodies, biomarkers, and immune responses using standardized laboratory or point-of-care formats. ELISA accounts for approximately 36.75% of the type structure, demonstrating the importance of antibody-antigen testing across veterinary laboratories and disease-surveillance programs. Companion-animal owners increasingly request preventive screening, while livestock producers require disease detection to protect herd productivity and biosecurity. Rapid diagnosis can support treatment selection, isolation decisions, vaccination strategies, and outbreak management. Veterinary clinics increasingly use immunodiagnostics for canine heartworm, tick-borne infections, feline viral diseases, gastrointestinal pathogens, and other common conditions. Livestock testing supports cattle, pig, and poultry disease surveillance. Rising pet ownership, animal-health expenditure, food-safety requirements, and One Health initiatives continue strengthening Veterinary Immunodiagnostics Market demand across clinical and agricultural settings.

RESTRAINT

"Diagnostic cost and limited laboratory infrastructure restrict adoption across lower-resource veterinary environments."

The Veterinary Immunodiagnostics Market faces restraints from diagnostic equipment costs, consumable expenses, veterinary laboratory availability, technical training requirements, and uneven healthcare infrastructure. Automated analyzers and connected platforms can improve diagnostic workflows but require capital investment, maintenance, consumables, software integration, and trained personnel. Radioimmunoassay represents approximately 9% of the report type structure and remains more specialized because alternative immunoassay technologies can provide simpler workflows without radioactive reagents. Rural veterinary practices and livestock operations may also face logistical barriers involving sample transport, cold-chain requirements, limited specialist access, and laboratory turnaround times. Rapid tests help address some of these limitations, but performance depends on appropriate sample collection, test handling, disease prevalence, and clinical interpretation. Cost-sensitive animal owners and livestock producers can delay testing when diagnostic expenses compete with treatment costs. These constraints encourage manufacturers to develop simpler, room-temperature-stable, portable, and lower-cost Veterinary Immunodiagnostics Market solutions.

OPPORTUNITY

"Expansion of connected point-of-care diagnostics creates significant veterinary testing opportunities."

The Veterinary Immunodiagnostics Market has substantial opportunities through connected point-of-care testing, automated readers, cloud-based diagnostic interpretation, multiplex assays, and artificial intelligence-supported veterinary workflows. Rapid Tests represent approximately 31% of the type framework used throughout this report, creating an important commercialization pathway for veterinary clinics, mobile services, livestock farms, shelters, and field surveillance. Modern point-of-care systems can automatically scan lateral-flow tests and transfer results into practice information systems, reducing manual documentation and subjective interpretation. Companion-animal practices particularly benefit because same-visit results can support immediate treatment or follow-up decisions. Livestock applications also create opportunities for decentralized testing where transporting samples to centralized laboratories can delay biosecurity decisions. Manufacturers can differentiate through multiplex panels, improved sensitivity, simplified workflows, longer shelf life, room-temperature storage, portable readers, and digital connectivity. Integration with reference laboratories and specialist networks further expands Veterinary Immunodiagnostics Market opportunities by connecting rapid screening with confirmatory and advanced diagnostic services.

CHALLENGE

"Maintaining assay accuracy across diverse animal species and disease conditions remains challenging."

A central Veterinary Immunodiagnostics Market challenge is maintaining reliable sensitivity and specificity across different species, pathogens, disease stages, sample types, and clinical conditions. Immunodiagnostic performance can vary depending on antigen concentration, antibody development, vaccination status, cross-reactivity, sample quality, and timing of infection. Canine applications represent approximately 33% of the application framework, but veterinary suppliers must also validate products for feline, cattle, pigs, poultry, equine, and other animals. A test optimized for 1 species or pathogen cannot automatically be transferred to another clinical context. False-negative results can delay treatment or disease-control measures, while false-positive results can create unnecessary interventions. Multiplex assays introduce additional validation requirements because multiple analytes must perform reliably within a single platform. Manufacturers therefore require extensive analytical testing, field validation, quality control, reagent standardization, and regulatory documentation. Maintaining accuracy while reducing test time remains a central challenge across the Veterinary Immunodiagnostics Market.

Veterinary Immunodiagnostics Market Segmentation

The Veterinary Immunodiagnostics Market is segmented by diagnostic technology and animal application according to disease prevalence, testing frequency, clinical workflow, and diagnostic setting. By type, Enzyme-Linked Immunosorbent Assay (ELISA) represents approximately 36.75% share, Rapid Tests account for 31%, Radioimmunoassay represents 9%, and Other technologies hold 23.25%, totaling 100%. By application, Canine accounts for approximately 33%, Cattle 17%, Feline 16%, Pigs 10%, Poultry 8%, Equine 7%, and Other applications 9%, totaling 100%. Companion-animal demand supports rapid point-of-care testing, while livestock applications depend strongly on herd surveillance, biosecurity, infectious-disease control, and laboratory screening.

By Type

Based on Type the global market can be categorized in to Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay, Rapid Tests, Other.

• Enzyme-Linked Immunosorbent Assay (ELISA): Enzyme-Linked Immunosorbent Assay (ELISA) leads the Veterinary Immunodiagnostics Market with approximately 36.75% share. ELISA technology is widely used to detect antibodies or antigens in serum, plasma, milk, and other veterinary samples. Its established laboratory infrastructure, high analytical specificity, scalable batch processing, and compatibility with livestock surveillance support substantial adoption. Veterinary laboratories use ELISA for infectious disease screening, herd-health programs, vaccination monitoring, and confirmatory testing. Companion-animal point-of-care products also incorporate ELISA principles in rapid assay formats. 

• Radioimmunoassay: Radioimmunoassay accounts for approximately 9% of the Veterinary Immunodiagnostics Market type framework. The method uses radiolabeled components to measure target substances through highly sensitive antigen-antibody reactions. Veterinary applications historically include hormone analysis, endocrine testing, reproductive assessment, and specialized laboratory research. The category remains smaller than ELISA and Rapid Tests because radioactive reagents require specialized handling, storage, disposal procedures, laboratory controls, and trained personnel. Modern chemiluminescent, fluorescence, and enzyme-based immunoassays increasingly provide alternatives for many routine diagnostic applications.

• Rapid Tests: Rapid Tests represent approximately 31% of the Veterinary Immunodiagnostics Market type framework and are gaining adoption because veterinarians increasingly require diagnostic results during the same clinical visit. Lateral-flow and rapid immunoassay formats detect antigens or antibodies in whole blood, serum, plasma, feces, urine, and other veterinary samples depending on the disease target. Modern canine multiplex tests can identify exposure or infection associated with 7 vector-borne pathogens from a single testing workflow. Rapid tests are widely used for heartworm, feline leukemia virus, feline immunodeficiency virus, parvovirus, Giardia, tick-borne infections, and reproductive assessment.

• Other: Other technologies account for approximately 23.25% of the Veterinary Immunodiagnostics Market and include fluorescence immunoassays, chemiluminescent immunoassays, immunofluorescence, specialized immunoassay analyzers, and emerging multiplex formats. These technologies address applications where laboratories or clinics require quantitative measurement, automation, higher throughput, or specialized biomarker detection beyond conventional ELISA and lateral-flow testing.

By Application

Based on Application the global market can be categorized in to Cattle, Pigs, Poultry, Feline, Canine, Equine, Other.

• Cattle: Cattle account for approximately 17% of the Veterinary Immunodiagnostics Market application framework. Immunodiagnostic testing supports herd-health surveillance, infectious disease control, reproductive management, milk-quality programs, trade certification, and livestock biosecurity. ELISA is particularly important because laboratories can process substantial sample volumes from dairy and beef herds using standardized antigen-antibody assays. Rapid tests also provide value where producers require field-level screening before laboratory confirmation. Cattle diagnostic programs can evaluate viral, bacterial, parasitic, and immune-related conditions depending on local disease priorities.

• Pigs: Pigs represent approximately 10% of the Veterinary Immunodiagnostics Market application framework. Swine producers use immunodiagnostic assays to support infectious disease surveillance, herd-health management, breeding operations, vaccination programs, and biosecurity decisions. High-density commercial production increases the importance of early pathogen identification because contagious diseases can spread rapidly within farms. ELISA and other laboratory immunoassays support high-throughput screening, while rapid formats can provide preliminary field-level information. The approximately 10% share reflects substantial global pork production and continued investment in disease prevention.

• Poultry: Poultry accounts for approximately 8% of the Veterinary Immunodiagnostics Market application framework. Commercial poultry producers require disease monitoring because flock density can accelerate transmission and create substantial production losses. Immunodiagnostic testing supports surveillance, vaccination assessment, infectious disease detection, breeding programs, and flock-health management. ELISA systems are particularly useful where laboratories need to process large sample numbers efficiently. Rapid tests can support preliminary screening where immediate farm-level decisions are required. The approximately 8% share reflects the large global poultry industry but also substantial use of molecular and other diagnostic technologies alongside immunodiagnostics

• Feline: Feline applications account for approximately 16% of the Veterinary Immunodiagnostics Market framework, supported by preventive companion-animal care, infectious disease screening, adoption programs, and routine veterinary examinations. Rapid immunodiagnostic products are commonly used to detect feline leukemia virus antigen and feline immunodeficiency virus antibodies using whole blood, serum, or plasma. Combination tests enable veterinarians to evaluate multiple infectious disease targets during a single clinic visit. The approximately 16% share reflects substantial pet-cat ownership and increasing preventive healthcare participation. Veterinary practices also use immunoassays for endocrine, gastrointestinal, infectious, and reproductive conditions depending on clinical needs. 

• Canine: Canine leads the Veterinary Immunodiagnostics Market application framework with approximately 33% share. Dogs receive extensive preventive screening for heartworm, Lyme disease, Anaplasma, Ehrlichia, gastrointestinal pathogens, parvovirus, and other infectious or immune-related conditions. Modern multiplex point-of-care immunodiagnostic tests can screen a single canine sample for 7 vector-borne pathogens, improving clinic workflow and broadening annual preventive testing. The approximately 33% share reflects high veterinary visit frequency, pet insurance participation, preventive-care programs, and broad availability of rapid diagnostic products.

• Equine: Equine accounts for approximately 7% of the Veterinary Immunodiagnostics Market application framework. Horses require immunodiagnostic testing for infectious disease surveillance, travel certification, competition requirements, breeding management, endocrine assessment, and herd-health protection. Field veterinarians benefit from rapid tests where immediate clinical or movement decisions are necessary, while reference laboratories provide specialized serology and confirmatory analysis. The approximately 7% share reflects a smaller animal population compared with cattle, pigs, poultry, dogs, and cats but comparatively high individual animal value across racing, sport, breeding, and recreational segments.

• Other: Other applications account for approximately 9% of the Veterinary Immunodiagnostics Market and include sheep, goats, aquaculture species, exotic animals, wildlife, laboratory animals, and specialized veterinary populations. Immunodiagnostic requirements vary according to disease ecology, production systems, conservation programs, research objectives, and zoonotic surveillance. Small-ruminant producers use serological testing for herd-health management, while wildlife programs use immunodiagnostics to monitor pathogens that can move between wild animals, livestock, and humans. Aquaculture applications are developing as commercial producers strengthen disease surveillance and biosecurity.

Veterinary Immunodiagnostics Market Regional Outlook

• North America

North America leads the Veterinary Immunodiagnostics Market with approximately 41.2% market share, supported by advanced veterinary hospitals, reference laboratories, point-of-care testing, companion-animal healthcare, and livestock disease surveillance. The USA represents the principal regional diagnostic center, with veterinary practices increasingly using immunoassays for heartworm, tick-borne infections, feline leukemia virus, feline immunodeficiency virus, gastrointestinal pathogens, and reproductive conditions. Canine applications account for approximately 33% of the global application framework, strengthening demand for rapid multiplex assays and preventive screening.

North America also maintains strong adoption of connected diagnostic readers and reference laboratory services. Modern canine immunodiagnostic platforms can evaluate a single sample for 7 vector-borne pathogens, supporting broader preventive testing during veterinary visits. ELISA represents approximately 36.75% of the global technology framework and remains important across reference laboratories, livestock surveillance, and confirmatory testing. Major suppliers maintain extensive veterinary clinic relationships and recurring consumable businesses throughout the region. Artificial intelligence, digital result integration, automated interpretation, and cloud-connected diagnostic platforms are increasingly incorporated into veterinary workflows. These capabilities reinforce North America’s approximately 41.2% share of the Veterinary Immunodiagnostics Market.

• Europe

Europe represents approximately 27.8% of the Veterinary Immunodiagnostics Market, supported by companion-animal healthcare, livestock disease-control programs, food-production biosecurity, veterinary laboratories, and established animal-health regulation. Cattle applications represent approximately 17% of the global application framework, making livestock immunodiagnostics important across European dairy and beef production. Veterinary laboratories use ELISA, rapid tests, fluorescence immunoassays, and other antibody-antigen technologies for surveillance, herd-health programs, infectious disease detection, and vaccination monitoring.

ELISA accounts for approximately 36.75% of the global type framework, reflecting its importance in standardized laboratory screening. European veterinary systems also emphasize surveillance for diseases affecting pigs, poultry, cattle, equine populations, and companion animals. Canine applications represent approximately 33% globally and benefit from preventive screening and increasing point-of-care testing in veterinary clinics. Regional suppliers compete through test accuracy, laboratory automation, multiplex capabilities, rapid turnaround, and standardized reagents. Europe also supports One Health approaches linking animal surveillance with food safety and zoonotic disease management. These characteristics maintain Europe at approximately 27.8% of the Veterinary Immunodiagnostics Market.

• Asia-Pacific

Asia-Pacific represents approximately 22% of the Veterinary Immunodiagnostics Market and provides substantial expansion opportunities through livestock production, companion-animal ownership, veterinary infrastructure development, and increasing disease-surveillance requirements. China, India, Japan, South Korea, and Southeast Asian economies support demand across cattle, pigs, poultry, canine, feline, and other animal categories. Pigs account for approximately 10% of the global application framework, while Poultry represents 8%, making livestock biosecurity an important regional driver.

Rapid Tests represent approximately 31% of the global technology framework and provide particular advantages where veterinary laboratories are distant from farms or clinical decisions are time-sensitive. Asia-Pacific livestock producers increasingly combine immunodiagnostics with molecular testing, vaccination programs, farm biosecurity, and outbreak surveillance. Companion-animal diagnostics are also expanding as urban pet ownership and preventive veterinary care increase. International and regional manufacturers compete through portable readers, rapid test kits, ELISA platforms, laboratory equipment, and diagnostic reagents. Local manufacturing can improve accessibility and reduce supply dependence. These factors support Asia-Pacific’s approximately 22% share while positioning the region for continued Veterinary Immunodiagnostics Market expansion.

• Middle East & Africa

Middle East & Africa accounts for approximately 4% of the Veterinary Immunodiagnostics Market, supported by livestock healthcare, animal disease surveillance, food-security programs, veterinary infrastructure development, and expanding companion-animal services. Cattle represent approximately 17% of the global application framework, making livestock testing particularly relevant across agricultural economies. Veterinary immunodiagnostics support screening for infectious diseases that can affect animal productivity, movement, breeding, and food supply.

Rapid Tests account for approximately 31% of the global type framework and offer practical advantages where centralized veterinary laboratory capacity is limited. Portable diagnostic formats can support field veterinarians, livestock farms, animal movement programs, and disease-control campaigns. Gulf markets increasingly support companion-animal veterinary hospitals and specialized diagnostic services, while African demand remains closely associated with livestock health and infectious disease surveillance. International suppliers often operate through distributors, government procurement programs, veterinary institutions, and laboratory partnerships. Improved reagent stability and simplified test procedures can expand adoption in challenging environments. These factors support Middle East & Africa at approximately 4% of the Veterinary Immunodiagnostics Market.

• Rest of the World

Rest of the World accounts for approximately 5% of the Veterinary Immunodiagnostics Market, covering demand across Latin America and other territories outside the principal regional classifications. Livestock production, companion-animal healthcare, veterinary laboratory modernization, animal exports, and disease surveillance support immunodiagnostic utilization. Cattle represent approximately 17% of the global application framework, making herd-health diagnostics particularly relevant across major livestock-producing economies. Canine and feline testing also expands as urban veterinary services develop.

ELISA accounts for approximately 36.75% of the global type framework and remains valuable for centralized laboratory screening, while Rapid Tests represent approximately 31% and support decentralized veterinary applications. Regional laboratories use immunodiagnostics for infectious disease surveillance, vaccination monitoring, animal movement certification, and herd-health management. Distribution partnerships are particularly important because international diagnostic manufacturers frequently rely on local veterinary suppliers to reach clinics and agricultural customers. Portable equipment, stable reagents, simplified sampling, and digital interpretation can improve adoption. These factors maintain Rest of the World at approximately 5% of the Veterinary Immunodiagnostics Market.

Key Industry Players

The Veterinary Immunodiagnostics Market includes global animal-health companies, diagnostic specialists, laboratory technology providers, and veterinary equipment suppliers. Abaxisinc, BioMerieux SA, Idexx Laboratories, Heska Corporation, Virbac SA, Zoetisinc, Randox Laboratories, Neogen Corporation, Woodley Equipment, Thermo Fisher Scientific, and Qiagen N.V. compete through rapid assays, ELISA platforms, laboratory technologies, point-of-care instruments, and diagnostic services. Competitive strategies increasingly emphasize multiplex testing, automation, digital connectivity, artificial intelligence, expanded test menus, and veterinary reference laboratory integration. Acquisitions and partnerships also reshape competition by combining instrument platforms with recurring diagnostic consumables. Suppliers differentiate through accuracy, turnaround time, clinical workflow integration, technical support, and geographic distribution.

List of Top Veterinary Immunodiagnostics Companies

• Abaxisinc
• BioMerieux SA
• Idexx Laboratories
• Heska Corporation
• Virbac SA
• Zoetisinc
• Randox Laboratories
• Neogen Corporation
• Woodley Equipment
• Thermo Fisher Scientific
• Qiagen N.V.

List of Top 2 Companies Market Share

• Idexx Laboratories: Estimated 24% share reflects reference laboratories, rapid immunoassays, connected analyzers, consumables, and veterinary relationships.
• Zoetisinc: Estimated 17% share reflects diagnostic platforms, point-of-care technologies, animal-health expertise, distribution, and clinical integration.

Investment Analysis and Opportunities

Investment opportunities in the Veterinary Immunodiagnostics Market increasingly center on point-of-care testing, multiplex immunoassays, connected readers, artificial intelligence, reference laboratories, and livestock disease surveillance. Rapid Tests represent approximately 31% of the technology framework, creating opportunities for portable platforms delivering actionable results during veterinary visits or farm investigations. Asia-Pacific accounts for approximately 22% of market share and offers expansion potential through veterinary infrastructure, companion-animal healthcare, and livestock biosecurity. Additional investment opportunities include reagent manufacturing, automated ELISA processing, cloud connectivity, diagnostic software, regional laboratories, and distribution networks. Companies combining instruments, recurring consumables, data integration, and specialist support can strengthen long-term veterinary customer relationships.

New Product Development

New product development in the Veterinary Immunodiagnostics Market focuses on multiplex assays, rapid lateral-flow tests, automated readers, digital connectivity, artificial intelligence, and broader disease panels. Modern canine immunodiagnostic platforms can evaluate 7 vector-borne pathogens from a single patient sample, expanding preventive screening without requiring separate individual tests. ELISA represents approximately 36.75% of the technology framework, encouraging continued improvements in automated processing, reagent stability, and laboratory throughput. Manufacturers are developing compact analyzers that automatically read immunoassays and transfer results into veterinary software. Additional innovation includes room-temperature-stable reagents, simplified sample preparation, quantitative immunoassays, cloud-based interpretation, and species-specific panels designed for companion animals and livestock.

Recent Developments

• March 2024: Idexx Laboratories expanded canine screening capabilities, enabling broader vector-borne pathogen detection through multiplex immunodiagnostics designed to improve preventive testing, clinical decision-making, and veterinary workflow efficiency.
• April 2024 – Zoetisinc: Zoetisinc completed its acquisition of Heska, integrating diagnostic instruments, consumables, software, imaging, and veterinary technologies to strengthen point-of-care capabilities and expand global clinic relationships substantially.
• September 2024: Neogen Corporation advanced animal-health testing solutions supporting livestock disease surveillance, laboratory efficiency, biosecurity, and veterinary decision-making through improved diagnostic reagents, assays, and testing capabilities globally.
• January 2025: Randox Laboratories expanded multiplex diagnostic capabilities for veterinary applications, supporting simultaneous biomarker detection, efficient sample utilization, laboratory automation, and broader infectious disease screening across animal populations.
• May 2025: Thermo Fisher Scientific strengthened veterinary laboratory capabilities through immunoassay reagents, instruments, workflow technologies, and analytical solutions supporting animal disease research, surveillance, and diagnostic testing globally.

Report Coverage

The Veterinary Immunodiagnostics Market report covers technology segmentation, animal applications, regional performance, competitive positioning, investment opportunities, product innovation, market dynamics, and industry developments. Type analysis includes Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay, Rapid Tests, and Other technologies, with ELISA accounting for approximately 36.75% market share. Application coverage includes Cattle, Pigs, Poultry, Feline, Canine, Equine, and Other animals, with Canine representing approximately 33%. Regional analysis covers North America, Europe, Asia-Pacific, Middle East & Africa, and Rest of the World. Coverage additionally evaluates multiplex testing, point-of-care diagnostics, laboratory automation, digital connectivity, disease surveillance, veterinary biosecurity, and immunoassay innovation.